Best Leukemia Doctors in Hyderabad — CION's Dedicated Leukemia Panel

Leukemia is best managed by a hematologist with leukemia experience — specifically a DM Clinical Hematology specialist with stem cell transplant capability. At CION, leukemia care is led by Dr. Basudev Pokhrel (Hematologist & SCT Specialist, DM Clinical Hematology), with co-leadership from Dr. Bharati Devi Gorantla (DM Medical Oncology, Adyar). Every case is reviewed by a multidisciplinary tumour board with hematology, medical oncology, and hematopathology together.

Acute and chronic leukemia are very different. Acute leukemias (AML — Acute Myeloid Leukemia, and ALL — Acute Lymphoblastic Leukemia) are medical emergencies — symptoms develop over days to weeks, blast cells crowd out normal blood cells, and untreated disease can be fatal within weeks. Same-day or next-day hospitalisation with immediate induction chemotherapy is standard. Chronic leukemias (CML — Chronic Myeloid Leukemia, and CLL — Chronic Lymphocytic Leukemia) progress slowly over months to years. CML is treated with oral TKI (imatinib, dasatinib, nilotinib) — most patients in chronic phase have near-normal life expectancy. CLL early-stage is often watched without treatment; progressive disease uses newer targeted agents like ibrutinib, acalabrutinib, or venetoclax.

Yes — CION provides stem cell transplant capability led by Dr. Basudev Pokhrel. Both autologous SCT (using patient's own cells) and allogeneic SCT (donor cells from sibling or matched unrelated donor) are offered. Candidacy depends on leukemia type, risk classification, age, performance status, donor availability, and other factors. Allogeneic SCT is the only curative therapy for many high-risk acute leukemias. Indications include high-risk AML in first remission, relapsed/refractory acute leukemia, CML in advanced phase, and selected aggressive lymphoid malignancies. SCT evaluation typically happens after induction chemotherapy achieves remission.

“7+3” is the standard induction chemotherapy for newly diagnosed AML — cytarabine for 7 days continuous infusion plus an anthracycline (daunorubicin or idarubicin) for 3 days. About 60–70% of patients achieve complete remission with first induction. Modern protocols add targeted agents: midostaurin for FLT3-mutant AML, gemtuzumab ozogamicin for CD33-positive AML, venetoclax + azacitidine for elderly/unfit patients who cannot tolerate intensive chemotherapy. CION's pathway includes molecular-guided induction selection.

Imatinib (Gleevec, and generic versions) was the first targeted therapy success story — transforming CML from a fatal disease to a chronic condition. It is a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL fusion protein driving CML. Treatment is oral, typically once daily, generally well-tolerated, and most patients in chronic phase achieve major molecular response. Monitoring with BCR-ABL transcript levels every 3 months. Newer second-generation TKIs (dasatinib, nilotinib) are options for first-line or for patients who don't respond well to imatinib. Treatment is usually indefinite, though selected patients with deep sustained molecular response may attempt treatment-free remission under careful monitoring.

Molecular markers increasingly guide treatment. For AML: FLT3 (ITD/TKD), NPM1, CEBPA, KIT, IDH1/IDH2, TP53 — each affects prognosis and therapy selection (e.g., midostaurin for FLT3, ivosidenib/enasidenib for IDH mutations). For ALL: Philadelphia chromosome (BCR-ABL), KMT2A rearrangements, T-cell vs B-cell lineage. For CML: BCR-ABL transcript level for monitoring, T315I mutation for ponatinib indication. For CLL: IGHV mutation status, TP53 mutation, 17p deletion — guide choice of ibrutinib vs chemoimmunotherapy. CION's pathway includes comprehensive molecular workup at diagnosis.

CAR-T cell therapy is approved for relapsed/refractory pediatric and young adult B-cell ALL (tisagenlecleucel), and for relapsed/refractory aggressive B-cell NHL. It involves harvesting the patient's own T cells, genetically modifying them to target CD19, and re-infusing them after lymphodepleting chemotherapy. CAR-T is delivered only at specialised accredited CAR-T centres after careful patient evaluation. CION coordinates CAR-T evaluation with accredited CAR-T centres for eligible patients. Cost remains high and access is limited but improving.

It depends on the type. Acute leukemias (AML, ALL) require hospitalisation for induction chemotherapy (typically 4–6 weeks total over the induction-consolidation period) due to profound neutropenia, transfusion needs, and infection risk. Chronic leukemias (CML, CLL) are largely outpatient — TKI for CML is oral medication; CLL is monitored as outpatient with treatment when indicated. Salvage therapy for relapsed disease and stem cell transplant require inpatient care.

A second opinion is valuable for leukemia — particularly because protocol choices and SCT decisions vary across centres. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your bone marrow report, flow cytometry, cytogenetics, molecular markers, and existing recommendation, and provides a documented opinion you can take anywhere.

Costs vary substantially by type. AML induction + consolidation (4–6 cycles, inpatient) ranges approximately ₹8,00,000 to ₹15,00,000+. ALL hyper-CVAD or pediatric-inspired protocols can range ₹10,00,000 to ₹20,00,000+ over the full treatment course. CML on imatinib (generic) ranges ₹1,00,000 to ₹3,00,000 per year. CLL with ibrutinib or venetoclax ranges ₹6,00,000 to ₹12,00,000+ per year. Autologous SCT ₹10,00,000 to ₹18,00,000. Allogeneic SCT ₹15,00,000 to ₹30,00,000+ depending on donor source and complications. For a detailed cost breakdown, see our leukemia treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate where feasible at start, with ongoing transparency. Aarogyasri, EMI, and cashless insurance accepted.